Skip to content
DataLookout
Menu

START-lungNCT07203053

A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 14 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites reduced: 19 → 13 locations
  2. Notable Eligibility criteria expanded, about 51 words
    • Secondary endpoints: details revised at 4 of 5 entries
    • Site details revised at 3 of 19 sites
  3. Minor Site details revised at 1 of 19 sitesv13
  4. Minor Site details revised at 1 of 19 sitesv12
  5. Minor Site details revised at 1 of 19 sitesv11
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Site details revised at 1 of 19 sitesv10
  2. Minor Site details revised at 1 of 19 sitesv9
  3. Minor Site details revised at 1 of 19 sitesv8
  4. Minor Site details revised at 2 of 19 sitesv7
  1. Notable Recruitment opened
    • Start date changed from estimate of May 2026 to Apr 15, 2026
    • Site details revised at 19 of 19 sites
    v6
  2. Minor Study sites: 1 to 19v4
  3. Minor Study sites: 0 to 1v3
  4. Minor Study title shortened, about 3 wordsv2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall survival rate at 12 months (12-month OS)
Timeframe: OS is defined as the time from the date of enrolment until death from any cause. Assessed for approximately up to 41 months.

Secondary (5)

Objective response rate (ORR)
Duration of response (DoR)
Disease control rate (DCR)
Progression-free survival (PFS)
Incidence, nature, and severity of adverse events

Arms and interventions

TarlatamabExperimental

Drugs: Tarlatamab

Sites

13 sites in 5 countries

Switzerland 4, Italy 3, Spain 3, France 2, Greece 1